Key facts
- Commodore Capital LP filed SCHEDULE 13G/A for Inhibikase Therapeutics, Inc. Common Stock, $0.001 par value (IKT).
- Disclosed ownership: 9.9%.
- Date of event: 31 Mar 2026.
Commodore Capital LP - 31 Mar 2026 SCHEDULE 13G/A Report for Inhibikase Therapeutics, Inc. Common Stock, $0.001 par value (IKT)
- Filing Manager
- Commodore Capital LP
- Reporting Manager
- Commodore Capital LP
- Symbol
- IKT
- Shares outstanding
- 141,969,091 shares
- Disclosed Ownership
- 14,054,940 shares
- Ownership
- 9.9%
- Form type
- SCHEDULE 13G/A
- Filing time
- 15 May 2026, 16:11:03 UTC
- Date of event
- 31 Mar 2026
- SEC
- View on sec.gov
Key filing fact
Commodore Capital LP disclosed 9.9% ownership in Inhibikase Therapeutics, Inc. Common Stock, $0.001 par value (IKT) on 31 Mar 2026.
Change
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 15 May 2026, 16:11.
Research use
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Reporting managers (4)
Names, ownership, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Commodore Capital LP | 9.9% | 14,054,940 | 0 | 14,054,940 | Michael Kramarz | Managing Partner | |
| Commodore Capital Master LP | 9.9% | 14,054,940 | 0 | 14,054,940 | Michael Kramarz | Authorized Signatory | |
| Robert Egen Atkinson | 9.9% | 14,054,940 | 0 | 14,054,940 | Robert Egen Atkinson | Authorized Signatory | |
| Michael Kramarz | 9.9% | 14,054,940 | 0 | 14,054,940 | Michael Kramarz | Authorized Signatory |
CIK / CUSIP context first